Lacrat

Ticagrelor, the active ingredient in Lacrat, is a P2Y12 receptor antagonist presented as a oral tablet for oral use. It reduces thrombotic cardiovascular events in patients with acute coronary syndrome and helps prevent stroke and myocardial infarction in individuals with atherosclerotic disease.

GNH USA supplies Lacrat as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ticagrelor is used to manage platelet‑mediated cardiovascular conditions, particularly in the setting of atherosclerotic disease and acute coronary events.

Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. Atherosclerotic disease: prevents recurrent stroke in patients with prior cerebrovascular events. Myocardial infarction secondary prevention: lowers the incidence of new myocardial infarction in patients with established coronary artery disease.

Ticagrelor may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dyspnea: shortness of breath, often transient. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Minor bleeding: bruising or gum bleeding. - Dizziness: occasional light‑headedness. - Diarrhea: loose stools in some patients.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Thrombocytopenia: markedly reduced platelet count. - Hyperuricemia: increased serum uric acid levels. - Bradyarrhythmia: unusually slow heart rate.

Before prescribing Ticagrelor, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess bleeding risk: review history of hemorrhage, recent surgery or trauma. Evaluate hepatic function: adjust use in patients with severe liver disease. Monitor renal function: consider dose adjustment in severe renal impairment. Avoid in patients with active pathological bleeding: contraindicated when bleeding is uncontrolled. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Ticagrelor interacts with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy, increasing thrombotic risk. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): combined use heightens bleeding potential.

Moderate Interactions (Monitor Closely): - Aspirin: additive antiplatelet effect may raise bleeding incidence. - NSAIDs (e.g., ibuprofen, naproxen): monitor for gastrointestinal bleeding. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin levels; consider dose adjustment.